Published in AIDS Weekly, September 15th, 2003
In a recent study, R. Akkina and colleagues at Colorado State University evaluated the efficacy of "anti-HIV ribozymes, RNA decoys and the newly described siRNAs."
"The therapeutic constructs consisted of an anti-CCR5 ribozyme to downregulate the HIV-1 cell surface co-receptor and ribozynmes targeted to viral mRNAs coding for the Tat, Rev and Env proteins," they explained. "The RAA decoy...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.